MX2009004791A - Derivados de anilinopiperazina t metodos de uso de los mismos. - Google Patents
Derivados de anilinopiperazina t metodos de uso de los mismos.Info
- Publication number
- MX2009004791A MX2009004791A MX2009004791A MX2009004791A MX2009004791A MX 2009004791 A MX2009004791 A MX 2009004791A MX 2009004791 A MX2009004791 A MX 2009004791A MX 2009004791 A MX2009004791 A MX 2009004791A MX 2009004791 A MX2009004791 A MX 2009004791A
- Authority
- MX
- Mexico
- Prior art keywords
- protein kinase
- aminothiazole
- kinase inhibitors
- carboxylic amides
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
La presente invención se refiere a derivados de anilinopiperazina novedosos de fórmula (I) (ver fórmula (I)) composiciones que comprenden los derivados de anilinopiperazina, y métodos para utilizar los derivados de anilinopiperazina para tratar o evitar un trastorno proliferativo, un trastorno anti-proliferativo, inflamación, artritis, un trastorno del sistema nervioso central, una enfermad cardiovascular, alopecia, una enfermedad neuronal, una lesión isquémica, una enfermedad viral, una infección fúngica, o un trastorno relacionado con la actividad de una proteína cinasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85542106P | 2006-10-31 | 2006-10-31 | |
PCT/US2007/022928 WO2008054749A1 (en) | 2006-10-31 | 2007-10-29 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004791A true MX2009004791A (es) | 2009-08-19 |
Family
ID=39253859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004791A MX2009004791A (es) | 2006-10-31 | 2007-10-29 | Derivados de anilinopiperazina t metodos de uso de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US8318735B2 (es) |
EP (1) | EP2078004B1 (es) |
JP (1) | JP4968860B2 (es) |
KR (1) | KR20090082440A (es) |
CN (1) | CN101568527A (es) |
AR (1) | AR063531A1 (es) |
AU (1) | AU2007314305B2 (es) |
CA (1) | CA2668255A1 (es) |
CL (1) | CL2007003138A1 (es) |
IL (1) | IL198487A0 (es) |
MX (1) | MX2009004791A (es) |
PE (1) | PE20080928A1 (es) |
TW (1) | TW200827359A (es) |
WO (1) | WO2008054749A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8163746B2 (en) * | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
MX2009004786A (es) * | 2006-10-31 | 2009-06-05 | Schering Corp | Derivados de anilinopiperazina y sus metodos de uso. |
JP5103604B2 (ja) * | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての2−アミノチアゾール−4−カルボン酸アミド |
WO2009054468A1 (ja) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | アゾールカルボキサミド化合物又はその塩 |
CN101910167A (zh) * | 2007-10-29 | 2010-12-08 | 先灵公司 | 噻唑甲酰胺衍生物及其治疗癌症 |
JP5230035B2 (ja) * | 2007-10-29 | 2013-07-10 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としてのチアゾール誘導体 |
AR070531A1 (es) * | 2008-03-03 | 2010-04-14 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
US8168794B2 (en) | 2008-03-03 | 2012-05-01 | Novartis Ag | Pim kinase inhibitors and methods of their use |
AU2009272034B2 (en) | 2008-07-17 | 2011-10-13 | Asahi Kasei Pharma Corporation | Nitrogenated bicyclic heterocyclic compound |
HUE026381T2 (en) | 2008-09-02 | 2016-06-28 | Novartis Ag | Kinase inhibitor picolinamide derivatives |
MX2011006509A (es) * | 2008-12-19 | 2011-10-19 | Genentech Inc | Compuestos heterociclicos y métodos de uso. |
EP2470183B1 (en) * | 2009-08-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
US8435976B2 (en) * | 2009-09-08 | 2013-05-07 | F. Hoffmann-La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
SG10201405568UA (en) * | 2009-09-08 | 2014-11-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
BR112012025480A2 (pt) | 2010-04-07 | 2020-08-18 | F. Hoffmann - La Roche Ag | composto, composição farmacêutica composta de um composto, uso do composto e método de tratamento de uma doença ou distúrbio |
CN103080106A (zh) * | 2010-07-06 | 2013-05-01 | 诺瓦提斯公司 | 用作激酶抑制剂的环醚化合物 |
GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
CA2845191A1 (en) | 2011-09-27 | 2013-04-04 | F. Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
CN103204824B (zh) * | 2012-01-12 | 2015-04-08 | 清华大学深圳研究生院 | 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用 |
WO2013138393A1 (en) * | 2012-03-12 | 2013-09-19 | Allergan, Inc. | Method of treating ophthalmic conditions with kinase inhibitors |
US8889870B2 (en) | 2012-03-12 | 2014-11-18 | Allergan, Inc. | Kinase inhibitors |
BR112014028954A2 (pt) | 2012-05-21 | 2017-07-18 | Novartis Ag | amidas de n-piridinila substituídas no anel como inibidores da quinase |
SI2900657T1 (sl) * | 2012-09-26 | 2020-07-31 | F. Hoffmann-La Roche Ag | Ciklični eter pirazol-4-il-heterociklil-karboksamidne spojine in načini uporabe |
JP2015534990A (ja) * | 2012-10-22 | 2015-12-07 | イージェニックス インコーポレイテッド | 誤制御されたeIF4Eに関連する疾患又は障害を治療又は予防するための組成物及び方法 |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
DK2945939T3 (da) * | 2013-01-15 | 2020-03-23 | Incyte Holdings Corp | Thiazolcarboxamider og pyridincarboxamidforbindelser anvendelige som pim-kinaseinhibitorer |
EA039704B1 (ru) * | 2013-01-15 | 2022-03-02 | Инсайт Холдингс Корпорейшн | Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
WO2014181813A1 (ja) * | 2013-05-10 | 2014-11-13 | 武田薬品工業株式会社 | 複素環化合物 |
WO2015013581A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9321766B1 (en) | 2014-10-06 | 2016-04-26 | Allergan, Inc. | Kinase inhibitors |
US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
EP3757102A1 (en) | 2016-03-17 | 2020-12-30 | F. Hoffmann-La Roche AG | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
US20190315775A1 (en) * | 2016-10-21 | 2019-10-17 | Keio University | Modified phenylphthalimide and pharmaceutical composition having same as active ingredient |
KR101935152B1 (ko) | 2017-05-31 | 2019-03-18 | 건국대학교 산학협력단 | 하이드라지드 유도체 및 이를 포함하는 항암제 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CN112979546B (zh) * | 2021-02-25 | 2023-01-31 | 中国药科大学 | 一类丁酰胆碱酯酶选择性抑制剂及其制备方法与用途 |
CN116969610B (zh) * | 2023-09-13 | 2024-01-02 | 杭州尚善若水环保科技有限公司 | 一种混合缓蚀阻垢剂 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU747705C (en) * | 1997-12-13 | 2004-09-23 | Bristol-Myers Squibb Company | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors |
US6413974B1 (en) * | 1998-02-26 | 2002-07-02 | Aventis Pharmaceuticals Inc. | 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
EP3222619A1 (en) | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Cyclic protein tyrosine kinase inhibitors |
KR20030016429A (ko) | 2000-07-26 | 2003-02-26 | 브리스톨-마이어스스퀴브컴파니 | 시클린 의존성 키나제의n-[5-[[[5-알킬-2-옥사졸릴]메틸]티오]-2-티아졸릴]카르복스아미드 저해제 |
US6495582B1 (en) | 2000-09-15 | 2002-12-17 | Vertex Pharmaceuticals Incorporated | Isoxazole compositions useful as inhibitors of ERK |
US6818663B2 (en) | 2002-05-17 | 2004-11-16 | Hoffmann-La Roches | Diaminothiazoles |
DE10250110A1 (de) | 2002-10-28 | 2004-05-13 | Bayer Cropscience Ag | Thiazol-(bi)cycloalkyl-carboxanilide |
FR2856685B1 (fr) * | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
CN101106990B (zh) | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
US8163746B2 (en) * | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
CN101808666A (zh) * | 2007-07-31 | 2010-08-18 | 先灵公司 | 作为抗癌治疗的抗有丝分裂剂和激光激酶抑制剂组合 |
-
2007
- 2007-10-29 KR KR1020097010904A patent/KR20090082440A/ko not_active Application Discontinuation
- 2007-10-29 MX MX2009004791A patent/MX2009004791A/es unknown
- 2007-10-29 CA CA002668255A patent/CA2668255A1/en not_active Abandoned
- 2007-10-29 US US12/447,710 patent/US8318735B2/en active Active
- 2007-10-29 AU AU2007314305A patent/AU2007314305B2/en not_active Ceased
- 2007-10-29 AR ARP070104789A patent/AR063531A1/es not_active Application Discontinuation
- 2007-10-29 PE PE2007001469A patent/PE20080928A1/es not_active Application Discontinuation
- 2007-10-29 JP JP2009534703A patent/JP4968860B2/ja not_active Expired - Fee Related
- 2007-10-29 CN CNA2007800483221A patent/CN101568527A/zh active Pending
- 2007-10-29 EP EP07853035.9A patent/EP2078004B1/en active Active
- 2007-10-29 WO PCT/US2007/022928 patent/WO2008054749A1/en active Application Filing
- 2007-10-30 CL CL200703138A patent/CL2007003138A1/es unknown
- 2007-10-30 TW TW096140812A patent/TW200827359A/zh unknown
-
2009
- 2009-04-30 IL IL198487A patent/IL198487A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP4968860B2 (ja) | 2012-07-04 |
AR063531A1 (es) | 2009-01-28 |
WO2008054749A1 (en) | 2008-05-08 |
TW200827359A (en) | 2008-07-01 |
JP2010508278A (ja) | 2010-03-18 |
AU2007314305B2 (en) | 2013-01-24 |
KR20090082440A (ko) | 2009-07-30 |
US8318735B2 (en) | 2012-11-27 |
US20100130465A1 (en) | 2010-05-27 |
EP2078004A1 (en) | 2009-07-15 |
CA2668255A1 (en) | 2008-05-08 |
CN101568527A (zh) | 2009-10-28 |
PE20080928A1 (es) | 2008-08-15 |
AU2007314305A1 (en) | 2008-05-08 |
CL2007003138A1 (es) | 2008-06-27 |
IL198487A0 (en) | 2010-02-17 |
EP2078004B1 (en) | 2015-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009004791A (es) | Derivados de anilinopiperazina t metodos de uso de los mismos. | |
MX2009004785A (es) | Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa. | |
MX2009004786A (es) | Derivados de anilinopiperazina y sus metodos de uso. | |
MX2010004875A (es) | Derivados de tiazol y metodos para utilizarlos. | |
WO2011025706A3 (en) | Heterocyclic amide compounds as protein kinase inhibitors | |
MX2010004876A (es) | Derivados de diamido tiazol como inhibidores de la proteina cinasa. | |
MX2010004880A (es) | Derivados heterociclicos de urea y tiourea, y metodos de uso de los mismos. | |
MX2010004878A (es) | Derivados de tioeter y eter heterociclico y metodos de uso de los mismos. | |
MY150032A (en) | Heterocyclic amide compounds as protein kinase inhibitors | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
TW200720268A (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | |
CY1116754T1 (el) | Παραγωγα νιτροκατεχολης ως αναστολεις της comt | |
WO2007149427A3 (en) | Tyrosine kinase inhibitors | |
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
TW200744586A (en) | Therapeutic compounds | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
HK1135103A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
EA200970738A1 (ru) | Ингибиторы активности akt | |
TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
DK1896421T3 (da) | Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET | |
UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
ZA201006782B (en) | Novel p2x7r antagonists and thier use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general |